Investment
Features
FeesSafety
Academy
More
Pluang+

Medtronic shares rated 'Buy' with 10%+ upside after strong Q4 growth and solid FY 2027 outlook.

Company Fundamentals
20 Aug 2026
Seeking Alpha
View Source
Bullish
pluang ai news

Medtronic is reaffirmed as a 'Buy' with shares expected to gain over 10% based on strong fundamentals and attractive valuation. The company posted its best organic revenue growth in a decade at 6.6% in Q4, driven by double-digit growth in its Cardiovascular and Diabetes segments. For fiscal year 2027, Medtronic targets organic revenue growth between 6.75% and 7.25%, and non-GAAP EPS of $5.90 to $6.00, despite challenges from tariffs and competition. Technical indicators show improving trends with key support and resistance levels identified around $89-$90 and $95-$96 respectively.

More News (MDT)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App